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Copper Intrauterine Devices and Tubal 
Infertility among Nulligravid Women
 
To the Editor:
 
 Hubacher and colleagues (Aug. 23 issue)
 
1
 
report that the use of copper intrauterine devices (IUDs)
is not associated with an increased risk of tubal occlusion
among nulligravid women. However, only 6 percent of the
women in the study had used an IUD. Accordingly, the
numbers used to test for an effect of the duration of IUD
use, an extremely important aspect of the study, were even
smaller. Only 44 women had used a copper IUD for more
than one year, of whom only 8 had tubal occlusion. Never-
theless, the odds ratios for tubal occlusion show a moder-
ate, nonsignificant trend of increasing risk with increasing
duration of IUD use (up to 6 months, 0.8 [95 percent
confidence interval, 0.4 to 1.8]; 7 to 12 months, 1.1 [95
percent confidence interval, 0.4 to 2.8]; and 13 months or
more, 1.3 [95 percent confidence interval, 0.6 to 3.2]). The
upper limits of these confidence intervals are consistent with
a marked effect of longer duration of IUD use on tubal in-
fertility.
We believe that the authors’ conclusion that contemporary
copper IUDs are safe is unwarranted. In a study of women
using IUDs, mostly devices containing copper, we reported
no deleterious effect on fertility of short-term use (up to 42
months) but strong evidence of such an effect after long-
term use (78 months or more).
 
2
 
 The study by Hubacher
et al. cannot rule out an adverse effect of these devices and
should be interpreted with caution.
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Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-
Rodríguez R. Use of copper intrauterine devices and the risk of tubal in-
fertility among nulligravid women. N Engl J Med 2001;345:561-7.
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Doll H, Vessey M, Painter R. Return of fertility in nulliparous women 
after discontinuation of the intrauterine device: comparison with women 
discontinuing other methods of contraception. BJOG 2001;108:304-14.
 
To the Editor:
 
 Hubacher and colleagues conclude that the
previous use of a copper IUD is not associated with tubal
occlusion, whereas chlamydia infection is. However, insert-
ing a “safe” IUD into a woman with an active chlamydial in-
fection can spread the infection to the upper genital tract,
resulting in pelvic inflammatory disease. Hubacher et al.
argue that an IUD is suitable for women who are not like-
ly to be at risk for sexually transmitted diseases, but chla-
mydia is common and is often unrecognized. The problem
is greater when an IUD is used for postcoital contracep-
tion and there is no opportunity for screening. In our
opinion, there is no reason to pardon the IUD.
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The authors reply:
 
To the Editor:
 
 Vessey and Doll state that long-term use
of copper IUDs may impair fertility. We disagree that our
case–control study did not include enough long-term use
of the IUD to show this putative effect. Vessey and Doll
cite odds ratios based on data from the control group of
infertile women; however, if their reasoning were applied to
our second control group of primigravid women, they might
have concluded that the longer a woman uses a copper IUD,
the less likely she is to become infertile. With these women
serving as controls, the odds ratios for tubal occlusion asso-
ciated with IUD use of 6 months or less, 7 to 12 months,
and 13 or more months were 1.4 (95 percent confidence
interval, 0.6 to 3.6), 1.0 (95 percent confidence interval,
0.3 to 3.0), and 0.6 (95 percent confidence interval, 0.3 to
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1.4), respectively. On the basis of the interpretation of our
data and the research of others,
 
1,2
 
 we stand by our conclu-
sion that copper IUDs do not impair fertility.
Chlamydia is common and often goes unrecognized, as
Verhoeven and colleagues state, but withholding the IUD
is not the answer if a woman says she is in a mutually mo-
nogamous relationship and has no clinical signs or symp-
toms of genital tract infection. In Belgium,
 
3
 
 the rates of
cervical chlamydial infections in women who opted for an
IUD were far lower than the rates in women who used oral
contraceptives (presumably as a result of a combination of
self-selection and careful screening). Perhaps, then, the fear
with regard to chlamydia is misdirected. At the time of in-
sertion of the IUD, bacteria can be pushed into the upper
genital tract; though they require validation, clinical stud-
ies indicate that the rates of pelvic inflammatory disease,
even in the presence of cervical infection, are within or be-
low the reported ranges without IUD insertion.
 
4
 
 Even when
sexually transmitted diseases are more prevalent, the in-
creased risk of pelvic inflammatory disease attributable to
IUD insertion is estimated to be very low (about 1 in 667).
 
5
 
Blaming the IUD for problems that require a bacterial patho-
gen is misleading. We believe that decisions about contracep-
tion should be based on the best available evidence, rather
than on clinical opinion. A growing body of literature indi-
cates that IUD use is far safer than previously thought.
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GB Virus C and Mortality from HIV Infection
 
To the Editor:
 
 The reports of Xiang et al.
 
1
 
 and Tillmann
et al.
 
2
 
 (Sept. 6 issue) further document that coinfection with
the apparently nonpathogenic flavivirus GB virus C (GBV-C,
or hepatitis G virus) prolongs survival in patients infected
with the human immunodeficiency virus (HIV). As the ac-
companying editorial
 
3
 
 emphasizes, there are no causal infer-
ences to be drawn from these observations, and the sugges-
tion that therapy with GBV-C might improve survival among
HIV-infected patients is correctly labeled as “premature.”
Although viral cross-talk of this sort has been described in
a number of other experimental systems,
 
4
 
 there are other
possible explanations for the “protective” effect. For exam-
ple, a potent cytotoxic-T-lymphocyte response to one viral
infection may reduce the level of cytotoxic-T-lymphocyte ac-
tivity directed to infection by a second virus.
 
5
 
 Persons who
have a strong cytotoxic-T-lymphocyte response to HIV may
have more difficulty mounting such a response to GBV-C
and may thus be less likely to clear GBV-C infection. Till-
mann et al. demonstrate no clear protective effect of expo-
sure to GBV-C (as determined by a test for anti-E2 anti-
bodies) but do demonstrate an obvious “protective” effect
in those in whom GBV-C RNA was detected. Failure to clear
active GBV-C infection may thus be an indirect marker of
a particularly potent cytotoxic-T-lymphocyte response to
HIV. This hypothesis, which can be readily tested, predicts
that “therapeutic” coinfection with GBV-C would have no
benefit for HIV-infected patients.
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To the Editor:
 
 We are concerned that the analysis of Xiang
et al. may not have taken into account the changes that oc-
curred in the management of HIV between 1988 and 2000.
These changes have dramatically decreased mortality from
HIV. On the basis of the data presented in the article by
Xiang et al., we calculate that 27 of the 144 patients with
GBV-C viremia (19 percent) enrolled in the study before
1990, as compared with 67 of the 218 patients without
GBV-C viremia (31 percent, P=0.005). It is unclear how
the investigators adjusted for this difference. The conclusion
regarding improved survival may be confounded by the era
of HIV therapy.
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To the Editor:
 
 In cases of coinfection with hepatitis C virus
(HCV) and HIV, differences in the progression of HIV in-
fection according to the HCV genotype have been report-
ed.
 
1
 
 Three studies of GBV-C and HIV — those of Yeo et al.,
 
2
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Xiang et al., and Tillmann et al. — included patients from
the United States and Europe. However, data on GBV-C
genotypes were not reported. An analysis of the association
between coinfection with various GBV-C genotypes and
the progression of HIV disease might help to explain the
mechanism underlying the delayed development of AIDS in
patients coinfected with HIV and GBV-C.
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The authors reply:
 
To the Editor: 
 
Macalalad and Snydman question whether
changes in the management of HIV confounded our analy-
sis, especially since there were fewer patients with GBV-C
viremia than patients without GBV-C viremia enrolled be-
fore 1990. We do not believe that such confounding oc-
curred, since we found no significant difference between the
patients with and those without GBV-C viremia in terms
of the proportion who began receiving care in the era be-
fore highly active antiretroviral therapy became available
(84 percent vs. 89 percent, P=0.20). However, to address
this issue, we stratified the patients according to the time
of entry into the clinic and repeated the Cox proportional-
hazards analysis with adjustment for the same prognostic
variables. The association between GBV-C viremia and im-
proved survival was significant for patients who began re-
ceiving care both before 1990 and after 1990. This rela-
tion held regardless of which year between 1990 and 1994
was chosen as the cutoff for stratification. We also conduct-
ed an analysis excluding the patients who began receiving
care before 1990 and including only those whose care began
between 1990 and 1996 to exclude any effect of highly active
antiretroviral therapy. This analysis confirmed the associa-
tion between GBV-C viremia and improved survival (adjust-
ed relative risk of death for patients who were GBV-C–
negative, 3.5 [95 percent confidence interval, 2.2 to 5.7]).
Takamatsu and colleagues question whether differences
in GBV-C genotype might explain the underlying mecha-
nism of delayed progression of HIV disease in persons
coinfected with GBV-C. All of our GBV-C isolates tested
to date with use of the method of Naito and Abe
 
1
 
 were of
genotype 2, reflecting the geographic origin of our pa-
tients. Given the low level of variation in amino acid se-
quences observed in different geographically and phyloge-
netically defined groups of viruses,
 
2
 
 it seems unlikely that
there are substantial biologic differences between genotypes
that would explain the underlying mechanism of the asso-
ciation we observed.
Mosier and Chisari question whether GBV-C viremia is
a marker of reduced GBV-C–specific cytotoxic-T-lympho-
cyte responses that occur as a result of a potent HIV-spe-
cific cytotoxic-T-lymphocyte response, which is ultimately
the reason for the delayed progression of HIV disease. Our
studies do not rule out the possibility of altered immuno-
logic responses to HIV or GBV-C in coinfected persons, and
differences in host cytokines and chemokines are probably
involved in the varying rate of progression of HIV disease
among infected persons. However, our in vitro model of
coinfection demonstrated diminished HIV replication in
the presence of GBV-C infection, strongly suggesting that
GBV-C replication has an effect on HIV replication that is
independent of cytotoxic-T-lymphocyte responses.
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gion. J Gen Virol 1997;78:1533-42.
 
To the Editor: 
 
We agree with Mosier and Chisari that the
reason for slower progression of disease in HIV-infected
patients who also harbor GBV-C still needs to be identified.
Although we favor the theory that GBV-C has a direct role
in ameliorating HIV infection, we cannot rule out the pos-
sibility that GBV-C is only a marker of a factor that has yet
to be identified. One such factor could be a potent cytotoxic-
T-lymphocyte response against HIV associated with a weak
cytotoxic-T-lymphocyte response against GBV-C, as sug-
gested by Mosier and Chisari. In that case, however, one
would expect to find more rapid progression among anti-
E2–positive patients than among patients who had not been
exposed to GBV-C. Furthermore, on the basis of the data
indicating that HIV replication is reduced by coinfection
with GBV-C in vitro, a direct interaction of the two virus-
es seems likely. Still, the cytotoxic-T-lymphocyte responses
to HIV and GBV-C antigens must be investigated. Our on-
going work includes the analysis of immune responses.
Takamatsu et al. raise the issue of GBV-C genotypes,
which we are also studying. The effect of coinfection with
various HCV genotypes in HIV-positive patients is contro-
versial.
 
1
 
 Furthermore, none of the studies analyzing the rel-
evance of the HCV genotype to the effect of coinfection
on HIV have taken into account coinfection with GBV-C.
Thus, these issues must be clarified in the light of new in-
formation on coinfection with GBV-C and HIV.
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Cardiac Rehabilitation
 
To the Editor:
 
 In his review, Ades (Sept. 20 issue)
 
1
 
 de-
scribes the benefits of cardiac rehabilitation in patients with
coronary heart disease. He notes the improvement that
takes place with cardiac rehabilitation in a range of psycho-
logical factors and symptoms, including anxiety, emotional
stress, lack of self-confidence, depression, social isolation,
and patient-reported quality of life. Ades reports that when
cardiac rehabilitation specifically includes psychosocial man-
agement, greater reductions in cardiac risk factors and mor-
bidity and mortality are evident.
We have found in our clinical work in cardiac rehabili-
tation that coexisting psychiatric symptoms and disorders
appear to play a critical part in influencing the psychoso-
cial status of patients with coronary heart disease and the
outcomes of cardiac rehabilitation. There is accumulating
evidence of distinct pathophysiologic pathways associated
with various psychiatric symptoms and disorders that have
also been shown to be independent risk factors for coronary
heart disease. We believe that the lack of critical evaluation of
the psychological symptoms of patients with coronary heart
disease, in terms of diagnosable psychiatric disorders with
concomitant treatment algorithms, results in underdiagnosis
and undertreatment of these psychiatric disorders.
We agree with Ades that psychosocial assessment of all
patients with recently diagnosed coronary heart disease is
needed, but we believe that the use of a standardized in-
strument that assesses the presence or absence of a wide
range of psychiatric illnesses is a critical component of the
evaluation of these patients. Only with a comprehensive
assessment of psychiatric disorders will the full benefit of
a multifactorial risk-reduction approach to the secondary
prevention of coronary heart disease be realized.
B
 
ETTINA
 
 B
 
ANKIER
 
, M.D.
A
 
NDREW
 
 B. L
 
ITTMAN
 
, M.D.
 
Harvard Medical School
Boston, MA 02115
bbankier@partners.org
 
1.
 
Ades PA. Cardiac rehabilitation and secondary prevention of coronary 
heart disease. N Engl J Med 2001;345:892-902.
 
To the Editor:
 
 In his review of cardiac rehabilitation, Ades
claims that “it has not been determined whether a cardiac-
rehabilitation program that consists of exercise alone reduc-
es mortality in current patient populations.” A brief search
of the 
 
Cochrane Library
 
 might have helped him. A recent
systematic review of 34 trials of exercise-based cardiac reha-
bilitation, including 20 trials reported since 1990 and involv-
ing a total of 8440 patients, shows an overall reduction in
mortality with this type of rehabilitation.
 
1
 
 Ades’s review is
nonsystematic in its coverage and consequently runs the risk
of biased assessment of the value of interventions. System-
atic reviewing of the literature, particularly with the use of
methods defined by the Cochrane Collaboration, has de-
veloped as a rational means to reduce the biases associated
with traditional narrative reviews.
 
2
 
 Evaluation of the effec-
tiveness of treatment should always be guided by the best
available evidence, starting with systematic reviews of large,
well-conducted, randomized controlled trials.
KAREN REES, PH.D.
SHAH EBRAHIM, F.R.C.P.
University of Bristol
Bristol BS8 2PR, United Kingdom
karen.rees@bristol.ac.uk
FOR THE COCHRANE HEART GROUP
1. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. 
Exercise-based rehabilitation for coronary heart disease (Cochrane Review). 
Cochrane Database Syst Rev 2001;1:CD001800.
2. Egger M, Davey Smith G, O’Rourke K. Rationale, potentials and 
promise of systematic reviews. In: Egger M, Davey Smith G, Altman DG, 
eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. 
London: BMJ Books, 2001:3-19.
Dr. Ades replies:
To the Editor: I agree with Bankier and Littman that psy-
chosocial assessment is needed in all patients with recently
diagnosed coronary heart disease. The cardiac-rehabilita-
tion program is one obvious setting in which this should
occur. Certain psychological characteristics, such as depres-
sion and social isolation, are associated with poor outcome
and predictably improve with rehabilitation. Although treat-
ment has not definitively been shown to decrease mortality
from cardiac causes or overall mortality, an improvement
in health-related quality of life with rehabilitation is predict-
able. Furthermore, depression or other psychological con-
ditions often impede patients from taking preventive med-
ications such as aspirin, beta-blockers, or lipid-lowering drugs
or from following a nutritional or exercise program.
As suggested by Rees and Ebrahim, I read the very thor-
ough Cochrane Review entitled “Exercise-Based Rehabil-
itation for Coronary Heart Disease.”1 Its focus is to com-
pare the value of interventions consisting of exercise alone
with comprehensive cardiac rehabilitation in terms of spe-
cific outcomes, such as overall mortality and mortality from
cardiac causes. Most of the patients in this analysis did not
receive exercise-only interventions. With regard to overall
mortality, only three studies of exercise alone reported since
1990 (and involving 554 patients) are included in the review,
and they are not assessed in a separate statistical analysis.
According to the data in those studies, the mortality rate
since 1990 in patients undergoing exercise alone is 8.1 per-
cent, as compared with a mortality rate of 9.2 percent in
controls; the difference is not significant (P=0.64).
 In view of lower overall mortality rates among patients
with coronary disease since the 1980s, even if contemporary
exercise-only rehabilitation provides a roughly 25 percent
reduction in mortality, the sample size required to demon-
strate this benefit needs to be far greater. I concur with the
comment in the Cochrane Review that “the incremental
benefit of cardiac rehabilitation on mortality in a world
where the majority of patients will receive thrombolysis,
The New England Journal of Medicine 
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aspirin, statins and increasingly ACE [angiotensin-convert-
ing–enzyme] inhibitors has not been studied adequately.”1
A lack of more recent data on exercise-only rehabilitation,
however, should not interfere with the evolution of rehabil-
itation programs into “secondary prevention centers,” which,
in addition to guiding exercise programs, are actively in-
volved in the measurement and treatment (by pharmacolog-
ic and lifestyle approaches) of risk factors such as hyperlip-
idemia and hypertension according to well-defined treatment
goals.2
PHILIP A. ADES, M.D.
University of Vermont College of Medicine
Burlington, VT 05405
philip.ades@vtmednet.org
1. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. 
Exercise-based rehabilitation for coronary heart disease (Cochrane Re-
view). Cochrane Database Syst Rev 2001;1:CD001800.
2. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for pre-
venting heart attack and death in patients with atherosclerotic cardiovascu-
lar disease: 2001 update. J Am Coll Cardiol 2001;38:1581-3.
Cephalosporin Allergy
To the Editor: We make the following observations about
the review of cephalosporin allergy by Kelkar and Li (Sept.
13 issue).1 First, anti-cephalosporin IgE antibody assays are
available and are used by clinicians in Australasia. Second,
specific haptenic determinants involved in hypersensitivity
to cephalosporins have been identified.2,3 Some of the cross-
reactivity between cephalosporins and penicillin G results
from the presence of IgE directed against a group as small
as the methylene substituent linking the side chain to the
rest of the penicillin molecule.2 Cephalosporins exhibit great-
er heterogeneity of allergenic determinants than penicillin
because of their extra side chain (R2) on the dihydrothi-
azine ring, and different fine structural recognition sites have
been identified in patients who are allergic to cefaclor.3,4
Our immunochemical studies have revealed a spectrum of
allergenic determinants ranging in specificity from side-chain
(R1 or R2) groups to compound determinants embracing
one or both ring structures.2-5
Third, our extensive experience in clinical and laboratory
testing suggests that cephalosporin allergy is much more
common than penicillin allergy (Table 1).5 We use radio-
immunoassays to measure major determinants (penicilloyl
and cephalosporoyl) and minor determinants (penicillanyl
and cephalosporanyl) for up to six different penicillins and
six different cephalosporins. The higher incidence of IgE
antibodies against cephalosporins was not anticipated and
most likely reflects both increased use of cephalosporins
and greater parenteral exposure to these drugs.5
KARL W. BAUMGART, M.B., PH.D.
Douglass Hanly Moir Pathology
Ryde, NSW 2113, Australia
kbaumgart@dhm.com.au
BRIAN A. BALDO, PH.D.
NSL Health
Melbourne, VIC 3000, Australia
1. Kelkar PS, Li JT-C. Cephalosporin allergy. N Engl J Med 2001;345:
804-9.
2. Harle DG, Baldo BA. Drugs as allergens: an immunoassay for detecting 
IgE antibodies to cephalosporins. Int Arch Allergy Appl Immunol 1990;
92:439-44.
3. Pham NH, Baldo BA. Beta-lactam drug allergens: fine structural recog-
nition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit 
1996;9:287-96.
4. Baldo BA. Diagnosis of allergy to penicillins and cephalosporins: struc-
tural and immunochemical considerations. Allergy Clin Immunol Int 
2000;12:206-12.
5. Baldo BA, Pham NH, Zhao A. Chemistry of drug allergenicity. Curr 
Opin Allergy Clin Immunol 2001;1:327-35.
To the Editor: Kelkar and Li recommend avoiding ceph-
alosporin use in patients with a history of penicillin allergy
and more specifically in patients who have a positive skin
test for allergy to penicillin. This strategy is not supported
by the data from the studies they cite. On the basis of their
Table 3, the authors could also have argued, inappropriately,
that the skin test itself reduces the risk of a reaction to ceph-
alosporin by 86 percent, from 4 in 34 (11.8 percent) to 8 in
486 (1.6 percent, P<0.001). They have partially misrepre-
sented the data from Shepherd and Burton,1 who really re-
ported four adverse reactions, not zero, in the 159 patients
with a negative skin test. If one uses these data to recalcu-
late the reported rates of adverse reactions to cephalospor-
ins in the groups with positive and negative skin tests (6 of
135 and 6 of 351, respectively) one finds no significant dif-
ference (P=0.08). However, the disparate qualities of the
data cited in Table 3 make combining these data and their
combined analysis invalid.
The authors’ statement that “these prospective studies
are too small to evaluate accurately the value of skin testing
in patients with a history of allergy to penicillin” is also not
supported by the data they present. In the single largest
study that has been conducted to explore this question,2
one reaction occurred in a group of 62 patients with posi-
tive skin tests for penicillin allergy who were exposed to par-
enteral cephalosporins. The 95 percent confidence interval
for this proportion, 0.016, was 0.004 to 0.085. Finally,
there are no data to support the authors’ recommendation
TABLE 1. RESULTS OF RADIOIMMUNOASSAYS FOR THE DETECTION 
OF IgE AGAINST “-OYL” AND “-ANYL” CONJUGATES OF 12 
DIFFERENT CEPHALOSPORINS AND PENICILLINS IN 1682 PATIENTS 
WITH POSSIBLE b-LACTAM ALLERGY.
DRUGS ELICITING A SPECIFIC IgE REACTION
NO. OF SERUM SAMPLES 
WITH A REACTION (%)
»1 b-lactam antibiotic 433 (25.7)
»1 Cephalosporin 397 (23.6)
»1 Penicillin 248 (14.7)
»1 Cephalosporin and 1 penicillin 212 (12.6)
Only »1 cephalosporins 185 (11.0)
Only »1 penicillins 36 (2.1)
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that penicillin skin tests be performed in persons with a his-
tory of adverse reaction only to cephalosporins.3,4
ERIC MACY, M.D.
Kaiser Permanente
San Diego, CA 92111
eric.m.macy@kp.org
1. Shepherd GM, Burton DA. Administration of cephalosporin antibiotics 
to patients with a history of penicillin allergy. J Allergy Clin Immunol 
1993;91:262. abstract.
2. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity 
reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204-15.
3. Anne S, Reisman RE. Risk of administering cephalosporin antibiotics 
to patients with histories of penicillin allergy. Ann Allergy Asthma Immu-
nol 1995;74:167-70.
4. Pre-Pen. Spokane, Wash.: Hollister-Stier Laboratories LLC, 1999 
(package insert).
To the Editor: Penicillin G has progressively been replaced
by other b-lactam antibiotics, in terms of both prescribing
habits and the induction of allergic reactions1,2; as a result,
skin testing with antigenic determinants of penicillin G is
no longer sufficient for evaluating patients for allergy to
b-lactams, and other determinants, such as those of amox-
icillin or cephalosporins, must be used instead.1-3 The as-
sumption that anaphylaxis from cephalosporins is rare is
based on insufficient evidence from individual case studies.
Anaphylaxis from b-lactams has become more common2
and is accompanied by a reduced rate of positive skin tests
for major determinants of penicillin G and an increased rate
of positive tests for minor determinants of other b-lactams,
including cephalosporins.2,3 The degree of cross-reactivity
among cephalosporins is not necessarily greater than that
between penicillins and cephalosporins. It depends on the
similarities in the chemical structures (nuclear or side-chain)
that are recognized by specific IgE antibodies or sensitized
T cells. For example, the cross-reactivity between cephadrox-
il and amoxicillin is greater than that between cephadroxil
and another unrelated side-chain cephalosporin.4
CRISTOBALINA MAYORGA, PH.D.
MARIA J. TORRES, M.D., PH.D.
Hospital Carlos Haya
29009 Malaga, Spain
labinves@hch.sas.cica.es
MIGUEL BLANCA, M.D., PH.D.
Hospital Universitario La Paz
28046 Madrid, Spain
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erance to other penicillins: study of the incidence in subjects allergic to
betalactams. Clin Exp Allergy 1990;20:475-81.
2. Torres MJ, Romano A, Mayorga C, et al. Diagnostic evaluation of a 
large group of patients with immediate allergy to penicillins: the role of 
skin testing. Allergy 2001;56:850-6.
3. Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions 
to cephalosporins: cross-reactivity and selective responses. J Allergy Clin 
Immunol 2000;106:1177-83.
4. Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a pen-
icillin and a cephalosporin with the same side chain. J Allergy Clin Immu-
nol 1996;98:671-7.
The authors reply:
To the Editor: Dr. Macy points out that the risk of a sys-
temic reaction to cephalosporin is low (1 in 62 in one study),
even among patients with a positive skin test for allergy to
penicillin.1 However, deaths caused by anaphylaxis from
cephalosporins do occur, and they seem to occur more fre-
quently among patients with a history of penicillin allergy.2
Dr. Macy cites a potential rate of systemic reactions of up
to 8.5 percent. We suggest the clinical circumstances of each
case should determine whether or not this level of risk can
be accepted. A careful review of the medical literature indi-
cates that there is insufficient evidence on which to base a
recommendation for a universally applicable strategy. We of-
fer skin testing for penicillin allergy as one strategy, partic-
ularly for patients who have a high likelihood of cephalospor-
in allergy and a history of a serious reaction to penicillin.
Dr. Macy implies that we recommend penicillin skin tests
for patients with a history of cephalosporin allergy. The
cross-reactivity of penicillin and cephalosporins suggests that
penicillin should be administered with caution in patients
with a history of a systemic reaction to cephalosporins. Pen-
icillin skin tests can be helpful in this clinical situation.
Drs. Baumgart and Baldo and Dr. Mayorga and colleagues
state that cephalosporin allergy is common and provide data
or references on tests for IgE antibodies or skin tests for
allergy to cephalosporins. Sensitization to cephalosporins and
drug reactions caused by hypersensitivity to cephalosporins
may be increasing. There is a distinction between sensiti-
zation, as revealed by IgE antibody tests or skin tests, and
clinical drug allergy.
Baumgart and Baldo and Mayorga et al. offer helpful de-
tails of the immunochemistry of b-lactam antibiotics. Study
of haptenic determinants of b-lactam antibiotics may lead
to the development of anti-cephalosporin IgE antibody as-
says and reagents for skin tests for immediate-hypersensitivity
reactions that can find a place in routine clinical practice.
However, the sensitivity and specificity of such tests do not
provide sufficient support for clinical decisions. Anaphylaxis
from b-lactam antibiotics is a life-threatening event.
JAMES T. LI, M.D., PH.D.
Mayo Clinic and Foundation
Rochester, MN 55905
li.james@mayo.edu
PRAMOD KELKAR, M.D.
Indianapolis Allergy and Asthma Physicians
Indianapolis, IN 46202-1287
1. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity 
reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204-15.
2. Pumphrey RS, Davis S. Under-reporting of antibiotic anaphylaxis may 
put patients at risk. Lancet 1999;353:1157-8.
Case 29-2001: Oncogenic Hypophosphatemic 
Osteomalacia
To the Editor: Several important issues were overlooked
in the Case Record of the 14-year-old boy with oncogenic
hypophosphatemic osteomalacia (Sept. 20 issue).1 Terek
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was correct in stating that oncogenic hypophosphatemic
osteomalacia has many similarities to X-linked hypophos-
phatemia. However, the onset of hypophosphatemia is not
delayed in X-linked hypophosphatemia. Terek did not con-
sider a diagnosis of autosomal dominant hypophosphatemic
rickets, which has incomplete penetrance and a variable age
of onset.2 Therefore, an affected child’s parent may carry
a mutation for autosomal dominant hypophosphatemic rick-
ets that is nonpenetrant, and the child may have delayed
phosphate wasting. It is important to note that weakness,
fatigue, and fracture are prominent features in patients with
autosomal dominant hypophosphatemic rickets who present
with delayed onset of disease and that these patients are
clinically indistinguishable from patients with oncogenic
hypophosphatemic osteomalacia.
Recent work regarding fibroblast growth factor 23 should
also have been addressed. Missense mutations in the gene
encoding fibroblast growth factor 23 cause autosomal dom-
inant hypophosphatemic rickets.3 In addition, fibroblast
growth factor 23 is highly expressed by tumors causing on-
cogenic hypophosphatemic osteomalacia.4 Fibroblast growth
factor 23 is therefore a strong candidate for “phosphatonin,”
the factor implicated as a cause of the phosphate wasting
in patients with oncogenic hypophosphatemic osteomala-
cia. The mutations that cause autosomal dominant hypo-
phosphatemic rickets stabilize fibroblast growth factor 23,
potentially elevating its concentration in serum and leading
to renal phosphate wasting.5 Because fibroblast growth fac-
tor 23 is produced in tumors causing oncogenic hypophos-
phatemic osteomalacia at high levels, the same net result as
in autosomal dominant hypophosphatemic rickets — elevat-
ed serum concentrations of the factor — would be present
in oncogenic hypophosphatemic osteomalacia, albeit by a
different mechanism. In conclusion, a diagnosis of autoso-
mal dominant hypophosphatemic rickets should be consid-
ered in patients with late-onset hypophosphatemia, especial-
ly in the light of the implications for genetic testing and
counseling.
KENNETH E. WHITE, PH.D.
STEVEN G. WAGUESPACK, M.D.
MICHAEL J. ECONS, M.D.
Indiana University School of Medicine
Indianapolis, IN 46202
mecons@iupui.edu
1. Case Records of the Massachusetts General Hospital (Case 29-2001). 
N Engl J Med 2001;345:903-8.
2. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rick-
ets/osteomalacia: clinical characterization of a novel renal phosphate-wast-
ing disorder. J Clin Endocrinol Metab 1997;82:674-81.
3. The ADHR Consortium. Autosomal dominant hypophosphatemic rick-
ets is associated with mutations in FGF23. Nat Genet 2000;26:345:8.
4. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of 
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Acad Sci U S A 2001;98:6500-5.
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tations stabilize FGF-23. Kidney Int 2001;60:2079-86.
Dr. Terek replies:
To the Editor: White and colleagues are correct to point
out that one cause of delayed-onset vitamin D–resistant
rickets is autosomal dominant hypophosphatemic rickets.
However, the importance of ruling out the presence of a
tumor cannot be overstated. In this case, the tumor was ma-
lignant and required multidisciplinary treatment, which not
only cured the tumor but also reversed the metabolic de-
rangements associated with vitamin D–resistant rickets.
Identification of fibroblast growth factor 23 as phosphato-
nin is an exciting advance in our understanding of the patho-
physiology of vitamin D–resistant rickets. The publication
of these findings postdated the clinicopathological confer-
ence at which I discussed the case.
RICHARD M. TEREK, M.D.
Brown Medical School
Providence, RI 02912
The Ethics of Placebo-Controlled Trials
To the Editor: Emanuel and Miller (Sept. 20 issue)1 char-
acterize the current debate about placebo-controlled trials
as a debate between two orthodoxies: placebo orthodoxy
and active-control orthodoxy. We used the term “placebo
orthodoxy” to describe the widely held but incorrect view
that the use of a placebo control is always better than the
use of an active control.2,3 Labeling our position “active-
control orthodoxy” wrongly suggests that we believe that
“if an effective therapy exists, the use of a placebo should
be prohibited” in all cases.1 We do, however, represent a
clinical-equipoise orthodoxy in believing that therapeutic
interventions in research must be consistent with physicians’
duty of care to patients.4 Mounting a trial requires genuine
disagreement among expert practitioners as to the preferred
treatment.4 If expert clinicians hold, as we believe they do,
that not treating baldness or headaches is consistent with
competent medical practice, then a placebo control is per-
missible. No competent clinician believes that withholding
treatment from a severely depressed or schizophrenic patient
is acceptable, and hence placebo-controlled trials in such cas-
es are unethical.5
Emanuel and Miller assert, but neither argue nor prove,
that the use of placebo controls and not active controls are
required for scientific validity.1 They further claim that the
requirement of scientific validity provides ethical justification
for the use of placebo, thus leaving no room for the limita-
tion of harm in trials. By claiming different moral standards
for clinical research and clinical care, they can no longer an-
swer the fundamental question in clinical research: When
is it ethically acceptable for physicians to suggest that their
patients enroll in a trial?4 This question is answered by clin-
ical equipoise, making the protection of patients a cost of
the ability to perform trials at all.
CHARLES WEIJER, M.D., PH.D.
Dalhousie University
Halifax, NS B3H 4H7, Canada
charles.weijer@dal.ca
KATHLEEN CRANLEY GLASS, D.C.L.
McGill University
Montreal, QC H3A 1W9, Canada
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The authors reply:
To the Editor: Central to research ethics is the distinction
between clinical care and clinical research.1-3 Weijer and
Glass muddle this distinction by claiming that “therapeu-
tic interventions in research must be consistent with phy-
sicians’ duty of care to patients.” The goal of all clinical
research is to improve health care by testing scientific hy-
potheses, not by providing personalized care. The funda-
mental duty of clinical investigators is to avoid exploiting
research participants.3,4 This is not ethically equivalent to
a physician’s therapeutic duty to provide optimal care to pa-
tients. Without an understanding of this difference, it would
never be ethical for investigators to perform research pro-
cedures on patient volunteers, such as blood sampling, lum-
bar punctures, positron-emission tomographic scanning, and
biopsies, which pose some risks without offering compen-
sating personal benefits.
In our article we describe criteria for the ethical justifi-
cation of placebo-controlled trials according to which they
should be ruled out if research participants would be ex-
posed to risks of substantial harm, including severe discom-
fort. These criteria are consistent with the responsibility to
avoid exploiting research participants. Consequently, Weijer
and Glass’s claim that our position leaves “no room for the
limitation of harm in trials” seems puzzling.
Finally, reflecting their conflation of clinical care and clin-
ical research, Weijer and Glass assert that “the fundamental
question in clinical research” is, “When is it ethically accept-
able for physicians to suggest that their patients enroll in a
trial?” They surely are mistaken. This is a secondary question.
It presupposes a satisfactory answer to the prior question:
When is it ethically justifiable to conduct a randomized
clinical trial? We provide clear guidance on this question
when the trial includes a placebo control.
EZEKIEL J. EMANUEL, M.D., PH.D.
FRANKLIN G. MILLER, PH.D.
National Institutes of Health
Bethesda, MD 20892-1156
fmiller@nih.gov
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Cesium-Induced Torsades de Pointes
To the Editor: Up to 50 percent of patients with cancer
seek help in the form of alternative medicine.1 Such ther-
apies may include cesium chloride, a blocker of the in-
ward-rectifying potassium channel that is used in animal
models to study the long-QT syndrome and torsades de
pointes.2 We report a documented case of cesium-induced
toxicity.
A 62-year-old man presented with recurrent syncope.
The patient had no history of cardiovascular disease, synco-
pe, or palpitations and no family history of sudden death.
Previously, the patient had had normal echocardiographic
and laboratory data. The patient underwent a naturopathic
treatment consisting of 2000 mg of cesium chloride four
times a day intravenously for two weeks for prostate cancer.
During treatment, he had his first episode of syncope. He
continued to take 1000-mg tablets of cesium chloride three
times a day. (The capsules were examined and were shown
to contain cesium chloride.) Two months later, the patient
was hospitalized because of recurrent syncope. The electro-
cardiogram showed a prolonged QT interval (approximate-
ly 700 msec) and ventricular ectopic beats arising from the
terminal part of the T wave (Fig. 1A). Runs of torsades de
pointes tachycardia were recorded on telemetry (Fig. 1B).
The serum potassium level was 2.8 mEq per liter. Analysis
of a blood sample revealed a plasma cesium level of 830
µmol per liter (reference range, 0.0045 to 0.0105) and an
erythrocyte cesium level of 3460 µmol per liter (reference
range, 0.0188 to 0.0564). The patient was treated with in-
travenous magnesium and potassium. The QT interval re-
mained prolonged and ventricular premature beats persisted
after normalization of the serum potassium level. The pa-
tient agreed to stop taking cesium chloride. After six months
of follow-up, the patient had not had any further episode of
syncope and the corrected QTc interval had returned to
normal.
In a series of 50 patients treated with oral cesium chlo-
ride for cancer, side effects such as nausea and diarrhea
were described, but not arrhythmia.3 In a recent case re-
port of syncope and polymorphic ventricular tachycardia
in a patient who was taking various naturopathic substanc-
es, cesium was thought to be the cause of the abnormali-
ties.4 In the present case, cesium-induced toxicity was doc-
umented. Hypokalemia may also have contributed to the
arrhythmia, but ventricular arrhythmia and prolongation
of the QT interval persisted after the normalization of the
serum potassium level. This report underscores the impor-
tance of clinical caution in the use of naturopathic medic-
inal therapies.
ARNOLD PINTER, M.D.
PAUL DORIAN, M.D.
DAVID NEWMAN, M.D.
University of Toronto
Toronto, ON M5B 1W8, Canada
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Figure 1. Electrocardiographic Findings in a Patient Who Was Receiving Long-Term Oral Cesium Therapy.
Panel A shows a standard 12-lead echocardiographic tracing obtained at admission after the patient’s third episode of syncope. The
QT interval of 680 msec is interrupted by frequent ventricular ectopic beats, all of which occur at the end of repolarization. Ventric-
ular ectopy interrupts a prolonged and bizarre-shaped TU complex of cardiac repolarization. Panel B shows all of the typical features
of torsades de pointes, with a short–long–short initiating sequence generated by a 1080-msec compensatory pause after a run of
ventricular premature beats, followed by a sinus beat and then by the first beat of a self-terminating polymorphic ventricular tach-
ycardia that starts at the end of a TU complex of repolarization. The plasma and erythrocyte cesium levels were approximately
60,000 times as high as the normal value at the time these tracings were obtained. The paper speed was 25 mm per second.
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